在PCOS中的胰岛素抵抗:月经功能障碍的病理生理机制和基于证据的治疗策略
Xianrui Chen1, Yu Wan1, Lingling Xie1
1The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Biology of reproduction
|August 30, 2025
概括
多囊卵巢综合症 (PCOS) 涉及胰岛素抵抗,破坏卵巢功能. 针对分子机制的个性化疗法以及微生物组干预等新兴疗法是治疗PCOS生殖和代谢问题的关键.
科学领域:
- 内分泌学
- 生殖医学
- 代谢疾病
背景情况:
- 多囊卵巢综合征 (PCOS) 影响5-10%的生育年龄妇女.
- 胰岛素耐药性 (IR) 是多达80%的多囊性卵巢综合症病例中的主要病理生理因素.
- 在PCOS中,IR有助于月经不规则和高雄性.
研究的目的:
- 阐明红外激光引起的卵巢功能障碍的分子机制.
- 评估目前和新兴的PCOS治疗策略.
- 强调PCOS的个性化管理方法.
主要方法:
- 对分子研究,临床试验和元分析的综合文献综述.
- 专注于胰岛素信号通路,治疗干预措施和种族差异 (东亚人口).
- 包括基因组和代谢组分析的进展.
主要成果:
- PCOS表现为选择性IR,影响新陈代谢信号传递,但不影响类固醇/ 甲基基路径,导致过高雄激素和无排卵.
- 东亚女性呈现显著的IR,通常BMI低于西方女性.
- 在PCOS中,IR会加剧心脏代谢风险和心理困扰.
结论:
- 了解IR-卵巢功能障碍的相互作用对于有效的PCOS治疗至关重要.
- 通过将分子洞察与数字健康工具相结合,可以提供个性化,多学科的PCOS护理.
- 解决PCOS的生殖和代谢方面可以改善患者的治疗结果.
相关概念视频
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
Pathophysiology of Diabetes
1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Insulin: Dosing Regimen and Adverse Effects
253
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
253
Hormonal Regulation of the Menstrual Cycle
688
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
688


